Blue Water Biotech, Inc. filed a Current Report on Form 8-K/A to correct the number of shares issued and outstanding following a share exchange agreement with Proteomedix AG, in which Onconetix acquired all of the issued and outstanding equity interests of Proteomedix in exchange for newly issued shares of common stock and preferred stock of Onconetix.